Foundation Medicine launches FoundationOne MRD molecular residual disease test

  • Foundation Medicine launched FoundationOne MRD, targeting earlier detection of cancer recurrence to expand its footprint in longitudinal cancer monitoring.
  • Positioned as a differentiated offering combining two genomic approaches, aiming to raise sensitivity while preserving specificity in real-world use.
  • Accelerated turnaround times could support faster clinical decisions, strengthening competitiveness in the fast-growing MRD testing market.
  • Medicare coverage for recurrence monitoring in early-stage breast cancer across all subtypes lowers adoption friction, supporting near-term commercial uptake.
  • Launch follows Roche’s SAGA Diagnostics acquisition, signaling portfolio integration to broaden access with plans for a global rollout.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Foundation Medicine Inc. published the original content used to generate this news brief on May 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.